secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2022-10-24T23:59:59+00:00
Accession:  0001628280-22-026895
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine amends charter and bylaws upon IPO closing
---------------------------------------------------------

- Third amended charter authorizes 775M shares common and 10M shares undesignated preferred.
- Bylaws eliminate stockholder written consent and restrict special meetings.
- Advance notice procedure adopted for stockholder proposals and director nominations.
- Changes became effective immediately prior to IPO closing on October 19, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828022026895/0001628280-22-026895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828022026895/prime-closing8xk102222.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-026895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer